Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Biogazelle Serves as Reference Laboratory for Bio-Rad's ddPCR System

Published: Monday, September 30, 2013
Last Updated: Monday, September 30, 2013
Bookmark and Share
Biogazelle’s and Bio-Rad’s long-term partnership extends.

Biogazelle has announced that it is serving a reference laboratory for Bio-Rad’s QX200™ Digital Droplet PCR™ system (ddPCR) in Europe. This extends Biogazelle’s and Bio-Rad’s long-term partnership for PCR-based solutions.

As a reference laboratory, Biogazelle uses ddPCR in its R&D programs and shares its ddPCR user experience with the PCR community.

In addition, Biogazelle is acting as a ddPCR service provider for third parties who are interested in outsourcing a study. In addition, the Biogazelle laboratory also serves as a live research environment for prospective QX200 system customers.

Professor Jo Vandesompele, co-founder of Biogazelle, welcomes the agreement: "We are a young and dynamic company, eager to learn from and to teach the PCR research community. Being a reference center for ddPCR is completely in line with our mission to address unmet needs through excellence in science and technology."

Digital PCR is a nucleic acid quantification method with unprecedented resolution and relative sensitivity. It can determine how many nucleic acid target molecules are present in a particular sample by counting how many miniaturized reactions are positive if the template is partitioned into 1000’s of parallel reactions.

The QX200 system uses droplets as partitions to perform ddPCR. It is a flexible and high throughput instrument with an optimal number of partitions per sample. Both probe and dye based assays can be used.

Biogazelle is at the forefront of digital PCR-based research, as it was one of the first European laboratories that had access to the technology in 2012. The co-founders are also co-author on the digital MIQE guidelines (Huggett et al., Clinical Chemistry, 2013).

Biogazelle is working on various ddPCR projects, including (i) gene copy number quantification to determine the stability of transgenic cells or organisms, (ii) splice variant quantification, (iii) quantification of pathogenic organisms, and (iv) rare event detection for cancer diagnostics and monitoring of patient response to treatment.

By sharing its expertise in assay development, experiment design and nucleic acid quantification, Biogazelle aims to serve the digital PCR community. In addition, Biogazelle will use its experience to provide digital PCR services for academic and industrial customers.

Dr. Jan Hellemans, co-founder of Biogazelle, acknowledges the great potential digital PCR holds for clinical diagnostics. "Data interpretation is quite straightforward and results can easily be shared and interpreted among different users because absolute concentrations are determined. Moreover, its inherently high precision, accuracy and relative sensitivity are relevant features for laboratory tests that are used in the clinic. Biogazelle is proud to accelerate ddPCR discoveries, bringing ddPCR closer to the clinic."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Biogazelle Receives €1.1M IWT Funding
Funding to develop lncRNA targeting cancer therapies.
Wednesday, August 12, 2015
Biogazelle has Established a Quality Management System
Company is ISO 17025 accredited for gene expression services.
Tuesday, February 03, 2015
Biogazelle Attracts New Investors
UGent spin-off Biogazelle attracts new investors QBIC Arkiv Fund, Foundation Majoie and SOFI to finance growth.
Tuesday, October 07, 2014
VIB Inks qBase+ Group Licensing Agreement with Biogazelle
VIB to accelerate its qPCR analyses by using qbase+ as the software.
Monday, May 20, 2013
Biogazelle Appoints Kris Vanhercke as Chief Operating Officer
New appointment strengthens business development and marketing expertise of Biogazelle.
Monday, September 24, 2012
Scientific News
13 Ways to Stop an Unseen Force from Disrupting Weighing
Download a free Mettler Toledo paper to discover how to halt static’s negative effects before the next weigh-in.
Flinders Ig Nobel Winner Cracks Global Anaesthetic
One of the world’s most in-demand anaesthetics can now be produced on the spot, thanks to the thermos-flask sized device that recently won Flinders University inventor Professor Colin Raston an Ig Nobel prize.
Resurrected Proteins Double Their Natural Activity
Researchers demonstrate method for reviving denatured proteins.
Genes That Protect African Children From Developing Malaria Identified
Variations in DNA at a specific location on the genome that protect African children from developing severe malaria, in some cases nearly halving a child’s chance of developing the life-threatening disease, have been identified in the largest genetic association study of malaria to date.
Messing With The Monsoon
Manmade aerosols can alter rainfall in the world’s most populous region.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Scientists Decode Structure at Root of Muscular Disease
Researchers at Rice University and Baylor College of Medicine have unlocked the structural details of a protein seen as key to treating a neuromuscular disease.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
New Test Detects All Viruses
A new test detects virtually any virus that infects people and animals, according to research at Washington University School of Medicine in St. Louis, where the technology was developed.
Inroads Against Leukemia
Potential for halting disease in molecule isolated from sea sponges.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos